Abstract
Resistance to non‐nucleoside reverse transcriptase inhibitors (NNRTIs) develops quickly and independently if they are used in combination with NRTIs or protease inhibitors (PIs) as rescue therapy, mainly due to the low genetic barrier of this class of drugs. In this study we examined clinical, therapeutic, and virologic characteristics in 88 patients with mutations conferring resistance to NNRTIs, and in 11 patients 1 year after stopping NNRTI therapy. Between patients administered Nevirapine (NVP) and those taking Efavirenz (EFV), no statistical differences were found in CD4 cell count, HIV viral load, time on NNRTI therapy, or number of PIs administered previously. A slow decline in the detectability of mutations encoding NNRTI resistance was found. J. Clin. Lab. Anal. 16:76–78, 2002. © 2002 Wiley‐Liss, Inc.
Keywords: HIV, resistance, salvage therapy, NNRTI
REFERENCES
- 1. D’Aquila RT, Hughe MD, Johnson VA, et al. 1996. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV‐1 infection. A randomized, double‐blind, placebo‐controlled trial. Ann Intern Med 124:1019–1030. [DOI] [PubMed] [Google Scholar]
- 2. Staszewski S, Morales‐Ramirez J, Tashima K, et al. 1999. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV‐1 infection in adults. N Engl J Med 341:1865–1873. [DOI] [PubMed] [Google Scholar]
- 3. Murphy RL, Katlama C, Johnson V, et al. 1999. The Atlantic study: a randomized, open‐label trial comparing two protease inhibitor (PI)‐sparing antiretroviral strategies versus a standard PI‐containing regimen, 48 week data. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; Abstract LB–22.
- 4. Durant J, Clevenbergh P, Halfon P, et al. 1999. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet 353:2195–2199. [DOI] [PubMed] [Google Scholar]
- 5. Baxter JD, Mayers DL, Wentworth DN, et al. 1999. Final results of CPCRA o46: pilot study of the short term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Antivir Ther 4(Suppl 1):43–56.16021870 [Google Scholar]
- 6. Schinazi RF, Larder BA, Mellors JW. 1997. Resistance table: mutations in retroviral genes associated with drug resistance. Int Antivir News 5:129–142. [Google Scholar]
- 7. Richman DD, Haulir D, Corbeil J, et al. 1994. Nevirapine resistance mutations of HIV type 1 selected during therapy. J Virol 68:1660–1666. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Salomon H, Wainberg MA, Brenner B, et al. 2000. Prevalence of HIV‐1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS 14:F17–F23. [DOI] [PubMed] [Google Scholar]
- 9. Casado JL, Hertogs K, Ruiz L, et al. 2000. Non‐nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor‐containing regimen. AIDS 24:F1–F7. [DOI] [PubMed] [Google Scholar]
- 10. Hanna G, Johson V, Kuritzkes D, et al. 2000. Patterns of resistance mutations selected by treatment of HIV type 1 infection with zidovudine, didanosine and nevirapine. J Infect Dis 181:904–911. [DOI] [PubMed] [Google Scholar]
- 11. Condra JH, Emini Ea, Gotlib L, et al. 1992. Identification of the HIV reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob Agents Chemother 36:1441–1446. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Clumeck N. 1999. Choosing the best initial therapy for HIV‐1 infection. N Engl J Med 341:1925–1926. [DOI] [PubMed] [Google Scholar]
- 13. Devereux H, Youle M, Johnson M, Loveday C. 1999. Rapid decline in detectability of HIV‐1 drug resistance mutations after stopping therapy. AIDS 13:F123–F127. [PubMed] [Google Scholar]